AstraZeneca Employee Traded On Icosavax Deal, SEC Says
By Sydney Price · July 8, 2026, 9:22 PM EDT
The U.S. Securities and Exchange Commission on Wednesday accused a former AstraZeneca Pharmaceuticals LP employee of using nonpublic information to trade ahead of the company's $1.1 billion acquisition of vaccine design...
To view the full article, register now.